Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD – Research Report), Hologic (HOLX – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report).
Gilead Sciences (GILD)
In a report issued on February 2, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $87.00. The company’s shares closed last Monday at $86.36, close to its 52-week high of $89.74.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $91.50, implying an 8.3% upside from current levels. In a report issued on January 18, Barclays also maintained a Hold rating on the stock with a $84.00 price target.
See today’s best-performing stocks on TipRanks >>
Hologic (HOLX)
In a report issued on February 3, Conor McNamara from RBC Capital maintained a Hold rating on Hologic, with a price target of $75.00. The company’s shares closed last Monday at $84.34.
According to TipRanks.com, McNamara is a 3-star analyst with an average return of
Currently, the analyst consensus on Hologic is a Moderate Buy with an average price target of $87.45, a 3.7% upside from current levels. In a report issued on January 20, Bank of America Securities also maintained a Hold rating on the stock with a $85.00 price target.
Zimmer Biomet Holdings (ZBH)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zimmer Biomet Holdings on February 5 and set a price target of $141.00. The company’s shares closed last Monday at $128.52.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
Currently, the analyst consensus on Zimmer Biomet Holdings is a Moderate Buy with an average price target of $135.00, a 4.7% upside from current levels. In a report issued on January 27, Stifel Nicolaus also maintained a Buy rating on the stock with a $142.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
- Gilead announces FDA approves Trodelvy in pre-treated HR+/HER2- breast cancer
- Gilead price target raised to $80 from $69 at Baird
- Gilead price target raised to $112 from $111 at Piper Sandler
- Gilead raises quarterly dividend 2.7% to 75c per share
- Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73
